Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

REGENERON PHARMACEUTICALS

(REGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Regeneron Pharmaceuticals : Merck seeks first U.S. authorization for COVID-19 pill

10/11/2021 | 06:34am EST

Oct 11 (Reuters) - Merck & Co Inc said on Monday it has applied for U.S. emergency use authorization for its drug to treat mild-to-moderate patients of COVID-19, putting it on course to become the first oral antiviral medication for the disease.

An authorization from the U.S. Food and Drug Administration could help change clinical management of COVID-19 as the pill can be taken at home.

The treatment, molnupiravir, cut the rate of hospitalization and death by 50% in a trial of mild-to-moderately ill patients who had at least one risk factor for the disease, according to data released earlier this month.

The interim efficacy data on the drug, developed with Ridgeback Biotherapeutics, had heavily dented the shares of COVID-19 vaccine makers and set off a scramble among nations, including Malaysia, South Korea and Singapore, to sign a supply deal with Merck.

The drugmaker has a U.S. government contract to supply 1.7 million courses at a price of $700 per course. Merck expects to produce 10 million courses of the treatment by the end of 2021.

It has also agreed to license the drug to several India-based generic drugmakers, which are expected to supply the treatment to more than 100 low- and middle-income countries.

Gilead Sciences Inc's infused antiviral remdesivir is generally given only once a patient is hospitalized.

Monoclonal antibody drugs from Regeneron Pharmaceuticals Inc and Eli Lilly, which are typically infused as well, have so far seen only limited use due to the difficulty in administering them.

Merck's shares opened roughly 1% higher before paring some gains to trade at $81.32.

(Reporting by Manas Mishra and Leroy Leo in Bengaluru; Editing by Arun Koyyur)


ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
GILEAD SCIENCES, INC. 0.29% 70.27 Delayed Quote.20.61%
REGENERON PHARMACEUTICALS -0.75% 643.35 Delayed Quote.33.17%
All news about REGENERON PHARMACEUTICALS
11/26MarketScreener's World Press Review - November 26, 2021
11/26Merck's COVID-19 pill significantly less effective in new analysis
RE
11/23Nykode Therapeutics in Vaccine Deal With Regeneron Worth Up to $925 Million
DJ
11/23Nykode, Regeneron to Team Up On Cancer, Infectious Disease Vaccines
MT
11/23Nykode Therapeutics Enters into Collaboration Agreement with Regeneron to Develop Innov..
CI
11/23Vaccibody AS announced that it expects to receive NOK 178.305538 million in funding fro..
CI
11/22Regeneron Extends Research Collaboration With Decibel Therapeutics; Decibel Shares Rise..
MT
11/22Decibel Therapeutics, Inc. Announces Extension of Research Term Under Strategic Collabo..
CI
11/19BioNTech's Skin Cancer Vaccine Candidate Wins US FDA's Fast Track Status
MT
11/18WALL STREET STOCK EXCHANGE : Trading is the new online gambling
More news
Analyst Recommendations on REGENERON PHARMACEUTICALS
More recommendations
Financials (USD)
Sales 2021 15 430 M - -
Net income 2021 7 903 M - -
Net cash 2021 5 814 M - -
P/E ratio 2021 9,19x
Yield 2021 -
Capitalization 67 266 M 67 266 M -
EV / Sales 2021 3,98x
EV / Sales 2022 4,46x
Nbr of Employees 9 766
Free-Float 81,9%
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 643,35 $
Average target price 697,52 $
Spread / Average Target 8,42%
EPS Revisions
Managers and Directors
Leonard S. Schleifer Co-President, Chief Executive Officer & Director
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
Robert E. Landry Chief Financial Officer & Executive VP-Finance
P. Roy Vagelos Chairman
Neil Stahl Executive VP-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
REGENERON PHARMACEUTICALS33.17%67 266
GILEAD SCIENCES, INC.20.61%88 146
BIONTECH SE326.89%84 049
WUXI APPTEC CO., LTD.24.40%64 416
VERTEX PHARMACEUTICALS-22.32%46 678
BEIGENE, LTD.34.56%32 622